Online inquiry

IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10758MR)

This product GTTS-WQ10758MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ADAMTSL5&ALB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Lama glama; Humanized
RefSeq NM_213604.3; NM_000477.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 339366; 213
UniProt ID Q6ZMM2; P02768
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10758MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14619MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ28MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ3525MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ515MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ10346MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ12439MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ7933MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ4341MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIW-8405
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW